SLC22A5 and hepatocellular carcinoma: Hu et al. reported, in an in vitro study, that sorafenib, the first-line TKI for treating patients with hepatocellular carcinoma, can inhibit the OCTN2 function by approximately 23% because of direct competitive inhibition of human OCTN2 [16].